Literature DB >> 2571965

Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.

D B Weiner1, Y Kokai, T Wada, J A Cohen, W V Williams, M I Greene.   

Abstract

The neu oncogene encodes a 185 kd glycoprotein (p185neu) with intrinsic tyrosine kinase activity. Sequencing data has demonstrated that oncogenic p185neu differs from c-neu by a single point mutation within the transmembrane region of the glycoprotein. This mutation results in the substitution of a glutamic acid residue for a nonpolar valine residue at amino acid position 664 of the rat neu gene product. Recent studies have demonstrated that this mutation results in specific aggregation of the p185neu oncoprotein mimicking ligand induced dimerization events. The cellular consequences of the aggregated phenotype may include the enzymatic activation of p185neu. We demonstrate that the oncoprotein p185neu possesses higher intrinsic tyrosine kinase activity and that this increase in enzymatic activity is apparent within the plasma membrane, manifesting itself through the increased tyrosine phosphorylation of substrates. Furthermore, the neu oncoprotein itself is also phosphorylated on tyrosine to a higher extent than the proto-oncoprotein. These results strongly link enzymatic activation of p185neu to cellular transformation events. To test directly the effect of p185neu tyrosine kinase activity on cellular transformation we constructed mutant p185neu devoid of ATP binding ability. This mutant protein is expressed at high levels, but is unable to induce the transforming phenotype. The point mutation within the transmembrane region of p185neu mimics aspects of ligand induced activation events including increases in the specific tyrosine kinase activity of the molecule leading to cellular transformation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571965

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.

Authors:  Y Mikami; J G Davis; K Dobashi; W C Dougall; J N Myers; V I Brown; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

3.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Authors:  R Murali; P J Brennan; T Kieber-Emmons; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development.

Authors:  Richard Chan; William R Hardy; Michael A Laing; Sarah E Hardy; William J Muller
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

5.  Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ros: biological function and substrate interaction.

Authors:  C S Zong; L H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

6.  ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea.

Authors:  Jingyuan Zhang; Quan Wang; Dunia Abdul-Aziz; Jonelle Mattiacio; Albert S B Edge; Patricia M White
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Authors:  B Wang; K E Ugen; V Srikantan; M G Agadjanyan; K Dang; Y Refaeli; A I Sato; J Boyer; W V Williams; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 10.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.